Haemophilia treatments are used to prevent or control bleeding episodes for people with haemophilia.
The funded treatments for haemophilia are changing. This means most people with haemophilia who access treatment will need to change the treatment they currently use.
Two new longer acting treatments are being funded for the first time. The longer acting treatments mean people with haemophilia will likely administer fewer injections.
Most people with haemophilia will need to change the brand of treatment they use, or the type of treatment they use. There will be a six month transition period, beginning 1 May 2019 and ending 1 November 2019, to change treatments.
You will be supported with the change in treatment by your Haemophilia Treatment Centre.
New long acting treatments are available from 1 May 2019
- From 1 May 2019, patients with haemophilia requiring prophylaxis treatment will have funded access to extended half-life Factor VIII and Factor IX treatments (Adynovate and Alprolix).
- Your clinician will decide with you if these longer acting treatments are right for you and what you need to do to manage the change.
Changes for people with haemophilia A using Factor VIII
- From 1 May 2019, two new products will be available as treatment options for people with haemophilia A – Advate and Adynovate.
- Advate is the preferred brand of short acting Factor VIII and Adynovate will be the only funded long acting Factor VIII.
- From 1 May to 31 October 2019 your Haemophilia Treatment Centre will support you to change to Advate or Adynovate. Most people with haemophilia A currently using Xyntha will need to change to Advate or Adynovate.
- From 1 November 2019 Xyntha will no longer be funded for the majority of people with haemophilia A.
- Your clinician will decide with you if it is appropriate for you to change brands and/or treatment. If your clinician considers you should stay on your current brand of Factor VIII they will apply for you to remain on Xyntha.
- If you are currently using Kogenate FS you will not need to change treatment.
Changes for people with haemophilia B using Factor IX
- From 1 May 2019, two new products will be available as treatment options for haemophilia B – RIXIBUS and Alprolix.
- RIXIBUS will be the only funded short acting Factor IX and Alprolix will be the only funded long acting Factor IX.
- From 1 May to 31 October 2019, your Haemophilia Treatment Centre will support you to change to RIXIBUS or Alprolix. All people with haemophilia B using BeneFIX will need to change to RIXIBUS or Alprolix
- From 1 November 2019, BeneFIX will no longer be funded.
Does everyone need to change their brand of treatment or the type of treatment?
No. Some people will be able to stay on their current treatment. Your clinician can apply for you to stay on Xyntha if they consider it would be inappropriate for you to change treatments. RIXIBUS will continue to be funded.
The way you receive your haemophilia treatment will remain the same even if you change treatments.
I am currently participating in a trial, do I need to change my treatment between 1 May 2019 and 1 November 2019?
No. Once the trial is completed you may need to change to the funded treatment that is appropriate for you. Your clinician will be able to help decide this with you.
What should I do if I have questions or concerns?
If you have any questions about which treatment is right for you, you should talk with your doctor or nurse at your Haemophilia Treatment Centre.
If you have any questions about the funding of your haemophilia treatments or access to these treatments, you can contact PHARMAC at firstname.lastname@example.org or 0800 66 00 50.
Last updated: 15 April 2019